Skip to content

Mistras Group MG Granted (in shares)

Granted (in shares) at other companies

Repligen logo
RepligenRGEN
$125.03
Genpact logo
GenpactG
$0.00
Ondas, Inc.
 logo
Ondas, Inc. ONDS
$10.29
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$32.52
Wingstop logo
WingstopWING
$0.00
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$34.31+175%

Other financials

Income statement

See full
Revenue$169.0M+4.6%
Gross profit$50.2M+8.4%
Operating income$4.7M+563%
Net income$2.4M+175%
EPS (diluted)$0.07+170%

Balance sheet

See full
Cash & equivalents$25.0M+34.8%
Total debt$216.7M+5.8%
Total equity$233.2M+17.4%
Total assets$572.7M+8.7%

Cash flow

See full
Operating cash flow$2.8M-50.2%
CapEx$6.0M+31.0%
Free cash flow-$3.2M-390%

Valuation

See full
Market cap$597.52M+153%
Enterprise value$789.23M+86.6%
P/E26.7×+10.7×
P/S0.8×+0.5×

Profitability

See full
Gross margin31.5%+1.8pp
Operating margin6.3%+1.6pp
Net margin3.1%+1.0pp
FCF margin0.6%-4.8pp

Returns & leverage

See full
Return on equity10.4%+2.7pp
Debt / equity0.9×-0.1×
Current ratio1.8×+0.3×

Where this comes from

Reported directly by Mistras Group in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.

The official record: Mistras Group’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mistras Group's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mistras Group's granted (in shares)?
Mistras Group (MG) reported granted (in shares) of $0.00 in Q1 2026.
How has Mistras Group's granted (in shares) changed year-over-year?
Mistras Group's granted (in shares) decreased by 100.0% year-over-year, from $9.06 to $0.00.
What does granted (in shares) mean?
The weighted average exercise price of stock options granted to employees and directors during the reporting period. This metric reflects the company's cost of equity-based incentives and the strike price set for new option awards.